Franklin Street Advisors’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Franklin Street Advisors’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-26,000	Closed	-$18K	–	161
2019 Q4	$18K	Sell	26,000 -20,000	-43%	-$14.1K	﹤0.01%	153
2019 Q3	$33K	Hold	46,000	–	–	﹤0.01%	155
2019 Q2	$36K	Hold	46,000	–	–	﹤0.01%	157
2019 Q1	$57K	Hold	46,000	–	–	0.01%	153
2018 Q4	$39K	Buy	46,000 +20,000	+77%	+$22.6K	0.01%	144
2018 Q3	$77K	Hold	26,000	–	–	0.01%	155
2018 Q2	$96K	Hold	26,000	–	–	0.01%	154
2018 Q1	$91K	Hold	26,000	–	–	0.01%	159
2017 Q4	$81K	Buy	26,000 +6,000	+30%	+$28.8K	0.01%	161
2017 Q3	$141K	Hold	20,000	–	–	0.02%	151
2017 Q2	$185K	Sell	20,000 -6,000	-23%	-$57.8K	0.03%	142
2017 Q1	$279K	Sell	26,000 -10,000	-28%	-$102K	0.05%	136
2016 Q4	$303K	Buy	+36,000	New	+$319K	0.05%	147

Franklin Street Advisors's NVLN Position: Q1 2020 in Review

Franklin Street Advisors sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2020, closing a stake of 26,000 shares — an estimated $18K sold.

Franklin Street Advisors first reported a position in NVLN in Q4 2016 and held it in 13 quarters. The position peaked at $303K in Q4 2016. 1 fund tracked by Wall St. Rank holds NVLN as of Q1 2020.

Franklin Street Advisors reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2020 after selling out during the quarter.
Franklin Street Advisors sold 26,000 Novelion Therapeutics Inc. Common Shares shares in Q1 2020, an estimated $18K.
Franklin Street Advisors first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 13 quarters.
Franklin Street Advisors's Novelion Therapeutics Inc. Common Shares position peaked at $303K in Q4 2016.
1 fund tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2020.

Based on Franklin Street Advisors's 13F filing for Q1 2020, filed 16 Apr 2020.